Cardiovascular Outcomes Trials For Opioid Agonists To Get FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Salix and Progenics’ appeal of FDA’s “complete response” letter for Relistor argues that potential safety issues for the opioid-induced constipation claim could be handled in a post-marketing study.
You may also be interested in...
AstraZeneca Seeking Patient Investors: Pipeline Holds Promise, But Long-Term
AstraZeneca’s mid-stage pipeline includes several interesting assets, particularly in oncology, and the company is determined to accelerate development of key projects under CEO Soriot’s turn-around plan. But even if the R&D team successfully executes on faster development timelines, the reward for investors is years away.
Relistor Expansion Plans In Question Following “Complete Response” Letter
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.